(24/7 MARKET NEWS) – Inhibikase Therapeutics, Inc. (Nasdaq: IKT) published two announcements this morning. The first being that it announced that the FDA lifted the Full Clinical Hold on IkT-148009 in Parkinson’s Disease and the second that it reported a publication demonstrating potential for c-Abl as a key therapeutic target in Parkinson’s Disease and related disorders
Inhibikase Therapeutics is trading at $0.9212, up $0.0112 (+1.23%), on volume of 2.2 million shares traded.
Its 52-week range is $0.4401 to 1.52. If it can break through the $1 resistance, its next key inflection point may be this morning’s premarket high of $1.30.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
